Zymeworks ZYME
NASDAQ ZYME
$29.15 -0.75 (-2.51%)
As of: Sep 4, 2026 · 3:58 PM EDT

Zymeworks (ZYME) Non-Current Assets (2021 - 2026)

Zymeworks (ZYME) posted Non-Current Assets of $92.5 million for Q1 2026, down 5.34% sequentially from $97.8 million in Q4 2025, and down 22.28% YoY from $119.1 million in Q1 2025.

Analysis

Zymeworks (ZYME) Non-Current Assets (2021 - 2026) Analysis & Trends

Zymeworks has reported Non-Current Assets for 6 years, with the latest figure at $92.5 million in Q1 2026.

  • Quarterly Non-Current Assets fell 22.28% year-over-year to $92.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $408.1 million (down 26.76% YoY) and the FY2025 annual result came in at $97.8 million, down 39.89% from the prior year.
  • Non-Current Assets retreated to $92.5 million in Q1 2026 per ZYME's latest filing, from $97.8 million in the prior quarter.
  • Over five years, Non-Current Assets peaked at $181.7 million in Q3 2023 and troughed at $92.5 million in Q1 2026.
  • A 5-year average of $136.3 million and a median of $132.1 million in 2024 frame the typical range for Non-Current Assets.
  • The sharpest annual moves came in 2023 and 2025: Non-Current Assets jumped 65.8% in 2023, then sank 39.89% in 2025.
  • Over 5 years, Non-Current Assets stood at $104.0 million in 2022, then soared by 61.46% to $168.0 million in 2023, then fell by 3.16% to $162.6 million in 2024, then tumbled by 39.89% to $97.8 million in 2025, then declined by 5.34% to $92.5 million in 2026.
  • According to Business Quant data, Non-Current Assets over the past three periods registered $92.5 million, $97.8 million, and $105.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Assets (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn 14.88 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 23.28 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn 1.96 Bn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 5.15 Bn
5 Revolution Medicines 44.33 Bn 44.33 Bn - 294.93 Mn
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 1.96 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 938.60 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn - 18.06 Bn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 468.65 Mn
10 Zymeworks 2.13 Bn 1.86 Bn - 98.58 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 98.58 Mn
Mar 31, 2026 92.54 Mn
Dec 31, 2025 97.76 Mn
Sep 30, 2025 105.56 Mn
Jun 30, 2025 112.26 Mn
Mar 31, 2025 119.06 Mn
Dec 31, 2024 162.64 Mn
Sep 30, 2024 143.38 Mn
Jun 30, 2024 132.14 Mn
Mar 31, 2024 159.93 Mn
Dec 31, 2023 167.95 Mn
Sep 30, 2023 181.73 Mn
Jun 30, 2023 181.72 Mn
Mar 31, 2023 174.37 Mn
Dec 31, 2022 104.02 Mn
Sep 30, 2022 109.61 Mn
Dec 31, 2021 100.91 Mn